Immunohistochemical (IHC) evaluation was used to determine protein expression levels of E2F1 and RAD54L in 17 patients with recurrent bladder cancer and 11 patients with non-recurrent bladder cancer. Here, E2F1 is linked to urinary bladder carcinoma.